Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
Nausea is the most common, affecting 13-18% in most studies, often during dose escalation
Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: Applying evidence to clinical practice
Avoid greasy, fried, spicy, or heavy foods
Are you a snacker
Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology
US$ 29.32
US$ 28.19
US$ 29.64
.webp)
US$ 26.90
